Skip to main content
SpringerLink
Log in

Latest updates from the MHRA

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Tamoxifen for breast cancer: drug interactions involving CYP2D6, genetic variants, and variability in clinical response. Drug Safety Update 4: A1, No. 4, Nov 2010

  2. Memantine pump device (Ebixa): risk of medication errors. Drug Safety Update 4: A2, No. 4, Nov 2010

  3. Oral bisphosphonates: oesophageal cancer risk - insufficient evidence of a link. Drug Safety Update 4: H1, No. 4, Nov 2010

  4. Tiotropium: safety studies of Spiriva Respimat. Drug Safety Update 4: H2, No. 4, Nov 2010

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Latest updates from the MHRA. React. Wkly. 1328, 2 (2010). https://doi.org/10.2165/00128415-201013280-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013280-00003

Keywords

Search

Navigation